We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
- Authors
Choi, Sun Ha; Jin, Cheng Cheng; Do, Sook Kyung; Lee, Shin Yup; Choi, Jin Eun; Kang, Hyo-Gyoung; Kim, Ji Hyun; Lee, Jang Hyuck; Hong, Mi Jeong; Lee, Won Kee; Jeong, Ji Yun; Shin, Kyung Min; Lee, Yong Hoon; Seo, Hyewon; Yoo, Seung Soo; Lee, Jaehee; Cha, Seung Ick; Kim, Chang Ho; Park, Jae Yong
- Abstract
Objective: This study was conducted to investigate whether polymorphisms in glycolysis-related genes are associated with clinical outcomes of patients with advanced-stage non-small cell lung cancer (NSCLC) undergoing chemotherapy. Methods: A total of 377 patients with NSCLC were enrolled. Sixty-five single-nucleotide polymorphisms in 26 genes involved in the glycolytic pathway were evaluated. The associations of the variants with the chemotherapy response and overall survival (OS) were analyzed. Results: Among the 65 variants investigated, PFKL rs2073436C>G and GPI rs7248411C>G significantly correlated with clinical outcomes after chemotherapy in multivariate analyses. PFKL rs2073436C>G was significantly associated with both a worse response to chemotherapy (adjusted odds ratio [aOR] = 0.64, 95% CI = 0.45–0.90, p = 0.01) and a worse OS (adjusted hazard ratio [aHR] = 1.35, 95% CI = 1.14–1.61, p = 0.001). GPI rs7248411C>G was significantly associated with both a better chemotherapy response (aOR = 1.58, 95% CI = 1.07–2.23, p = 0.02) and a better OS (aHR = 0.80, 95% CI = 0.66–0.98, p = 0.03). When stratified by tumor histology, PFKL rs2073436C>G was significantly associated with OS only in squamous cell carcinoma, whereas GPI rs7248411C>G exhibited a significant association with the chemotherapy response and OS only in adenocarcinoma. Conclusion: This result suggests that the PFKL rs2073436C>G and GPI rs7248411C>G are useful for predicting the clinical outcome of first-line paclitaxel-cisplatin chemotherapy in NSCLC.
- Subjects
LUNG cancer treatment; LUNG cancer prognosis; ADENOCARCINOMA; ANTINEOPLASTIC agents; CANCER chemotherapy; CELLULAR signal transduction; CISPLATIN; CONFIDENCE intervals; STATISTICAL correlation; GENETIC polymorphisms; GLYCOLYSIS; MULTIVARIATE analysis; ONCOGENES; PACLITAXEL; STATISTICAL sampling; SURVIVAL; TREATMENT effectiveness; SINGLE nucleotide polymorphisms; ODDS ratio
- Publication
Oncology, 2020, Vol 98, Issue 7, p468
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000504175